Diagnosis and treatment of primary central nervous system lymphoma

Current Oncology Reports

Volumn 7, Issue 1, 2005, Pages 47-54

  Gavrilovic, Igor T ^a   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; PROTEIN P53; RITUXIMAB; TEMOZOLOMIDE; TENIPOSIDE; THIOSULFATE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATAXIA; BLOOD BRAIN BARRIER; BRAIN EDEMA; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; CYTOGENETICS; DEMENTIA; DIAGNOSTIC IMAGING; DRUG PENETRATION; DRUG RESPONSE; EYE TUMOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMAGING SYSTEM; LEUKOENCEPHALOPATHY; MOLECULAR BIOLOGY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; URINE INCONTINENCE;

EID: 14044259398     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0025-x     Document Type: Review

References (55)

1. Camilleri-Broet S, Martin A, Moreau A, et al.: Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 1998, 110:607-612.
2. Gijtenbeek JM, Rosenblum MK, DeAngelis LM: Primary central nervous system T-cell lymphoma. Neurology 2001, 57: 16-718.
3. Henry JM, Heffner RR, Jr, Dillard SH, et al.: Primary malignant lymphomas of the central nervous system. Cancer 1974, 34:1293-1302.
4. Hormigo A, DeAngelis LM: Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma 2003, 4: 2-29.
5. Herrlinger U, Schabet M, Bitzer M, et al.: Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 1999, 43:219-226.
6. DeAngelis LM, Gutin PH, Leibel SA, Posner JB: Intracranial Tumors, edn 1. London: Martin Dunitz; 2002.
7. CBTRUS:Statistical Report: Primary Brain Tumors in the United States, 1995-1999. http://www.cbtrus.org. Accessed July 30, 2004.
8. Cote TR, Manns A, Hardy CR, et al.: Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996, 88:675-679.
9. Olson JE, Janney CA, Rao RD, et al.: The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results analysis. Cancer 2002, 95:1504-1510.
10. Tomlinson FH, Kurtin PJ, Suman VJ, et al.: Primary intracerebral malignant lymphoma: a clinicopathological study of 89 patients. J Neurosurg 1995, 82:558-566.
11. Phan TG, O'Neill BP, Kurtin PJ: Posttransplant primary CNS lymphoma. Neuro-oncol 2000, 2:229-238.
12. DeAngelis LM, Wong E, Rosenblum M, Furneaux H: Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma. Cancer 1992, 70:1607-1611.
13. Itoyama T, Sadamori N, Tsutsumi K, et al.: Primary central nervous system lymphomas: immunophenotypic, virologic, and cytogenetic findings of three patients without immune defects. Cancer 1994, 73:455-63.
14. Weber T, Weber RG, Kaulich K, et al.: Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 2000, 10:73-84.
15. Boonstra R, Koning A, Mastik M, et al.: Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Arch 2003, 443:164-169.
16. Zhang SJ, Endo S, Ichikawa T, et al.: Frequent deletion and 5′ CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res 1998, 58: 231-1237.
17. Deckert-Schluter M, Rang A, Weistler OD: Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system. Acta Neuropathologic 1998, 96: 57-162.
18. Camilleri-Broet S, Camparo P, Mokhtari K: Overexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients. Mod Pathol 2000, 13: 58-165.
19. Choi JS, Nam DH, Ko YH, et al.: Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas. Am J Surg Pathol 2003, 27:919-928.
20. Buhring U, Herrlinger U, Krings T, et al.: MRI features of primary central nervous system lymphomas at presentation. Neurology 2001, 57:393-396.
21. O'Neill BP, Dinapoli RP, Kurtin PJ, Habermann TM: Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): How much staging is enough? J Neurooncol 1995, 25:67-71.
22. Skolasky RL, Dal Pan GJ, Olivi A, et al.: HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci 1999, 163:32-38.
23. Antinori A, De Rossi G, Ammassari A, et al.: Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999, 17:554-560.
24. Singh A, Strobos RJ, Singh BM, et al.: Steroid-induced remissions in CNS lymphoma. Neurology 1982, 32:1267-1271.
25. Nelson DF, Martz KL, Bonner H, et al.: Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992, 23:9-17.
26. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000, 18: 144-3150.
27. DeAngelis LM, Seiferheld W, Schold SC, et al.: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002, 20:4643-4648.
28. DeAngelis LM, Yahalom J, Thaler HT, Kher U: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992, 10:635-643.
29. O'Brien P, Roos D, Pratt G, et al.: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000, 18: 19-526.
30. Pels H, Schmidt-Wolf IG, Glasmacher A, et al.: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003, 21:4489-4495.
31. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003, 21:4483-4488.
32. Posner JB: Neurologic Complications of Cancer. Philadelphia: F. A. Davis; 1995.
33. Correa DD, DeAngelis LM, Shi W, et al.: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004, 62:548-555.
34. Abrey LE, Moskowitz CH, Mason WP, et al.: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003, 21: 151-4156.
35. Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21:2726-2731.
36. Batchelo0r T, Carson K, O'Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21:1044-1049.
37. Sandor V, Stark-Vancs V, Pearson D, et al.: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998, 16:3000-3006.
38. Herrlinger U, Schabet M, Brugger W, et al.: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002, 51:247-252.
39. McAllister LD, Doolittle ND, Guastadisegni PE, et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51-60.
40. Reni M, Ferreri AJ: Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 2001, 80(Suppl 3):B113-B117.
41. de Smet MD, Vancs VS, Kohler D, et al.: Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 1999, 83:448-451.
42. Ciordia P, Hochberg F, Batchelor T. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma [abstract]. Proc ASCO 2000, 19:639.
43. Fischer L, Thiel E, Klasen HA, et al.: Response of relapsed or refractory primary central nervous system lymphoma (PCNS00L) to topotecan. Neurology 2004, 62:1885-1887.
44. Reni M, Ferreri AJ, Landoni C, Villa E: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 2000, 92:575-576.
45. Reni M, Mason W, Zaja F, et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004, 40: 682-1688.
46. Herrlinger U, Brugger W, Bamberg M, et al.: PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000, 54:1707-1708.
47. Pels H, Schulz H, Manzke O, et al.: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002, 59:213-216.
48. Wong ET, Tishler R, Barron L, Wu JK: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004, 101:139-145.
49. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM: Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 2004, 126:202-208.
50. Tosi P, Gherlinzoni F, Visani G, et al.: AZT plus methotrexate in HIV-related non-Hodgkin's lymphomas. Leuk Lymphoma 1998, 30:175-179.
51. Ferreri AJ, Blay JY, Reni M, et al.: Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003, 21: 66-272.
52. Corry J, Smith JG, Wirth A, et al.: Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998, 41:615-620.
53. Ferreri AJ, Guerra E, Regazzi M, et al.: Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004, 90:353-358.
54. Braaten KM, Betensky RA, de Leval L, et al.: BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003, 9: 063-1069.
55. Chang CC, Kampalath B, Schultz C, et al.: Expression of p53, c-Myc, or Bcl0-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 2003, 127:208-212.